2. Bicycle Therapeutics (NASDAQ:BCYC)
5-Year Revenue CAGR: 30.21%
No of Hedge Funds: 30
Bicycle Therapeutics (NASDAQ:BCYC) is a clinical-stage biopharmaceutical company pioneering a new class of medicines based on its proprietary bicyclic peptide technology. The company’s therapeutic molecules called “bicycles” are smaller, more stable, and cheaper to produce than monoclonal antibodies, which are laboratory-produced protein that acts like an antibody in the body’s immune system and are used for the diagnosis and treatment of many diseases, including some types of cancer.
Bicycle Therapeutics’ (NASDAQ:BCYC) core technology is based on the discovery of “bicycles” which are small peptides that can be used to target specific molecules in the body. These peptides are designed to be more stable and have a higher affinity for their targets than traditional monoclonal antibodies.
Bicycle Therapeutics’ (NASDAQ:BCYC) pipeline includes several promising molecules in various stages of development. The company’s lead internal program is BT8009, a bicycle toxin conjugate (BTC) molecule that targets tumors overexpressing Nectin-4. BT8009 is currently in a phase 1/2 trial and a phase 2/3 registrational trial. The company’s second candidate is BT5528, which targets high EphA2-expressing tumors and is in phase 1/2 development. The third clinical-stage internal program is BT7480, another Nectin-4/CD137 dual-targeting molecule in phase 1/2 trials.
BT8009 has shown promising efficacy data in an ongoing phase 1/2 trial in heavily pre-treated patients with metastatic urothelial cancer. The molecule demonstrated a 38% objective response rate (ORR) among 26 patients receiving a 5 mg/m² weekly dose. The median duration of response was 11.1 months in 10 patients, with five still undergoing therapy. BT8009 also showed promising early results in other cancers, such as ovarian, triple-negative breast, and non-small cell lung cancer.
BT5528 is another BTC molecule that targets EphA2, a receptor tyrosine kinase overexpressed in difficult-to-treat tumors. BT5528 has shown promising efficacy data in patients with metastatic urothelial cancer, achieving a 39% objective response rate (ORR) among 18 patients who received doses of 6.5 mg/m², 8.5 mg/m², or 10 mg/m² every other week. The median duration of response was four months among seven patients.
Bicycle Therapeutics (NASDAQ:BCYC) has over 344 patents and 567 patent applications in various jurisdictions. Their patent portfolio consists of novel scaffolds and linkers, platform technology, bicyclic peptides, and related conjugates. Bicycle Therapeutics (NASDAQ:BCYC) is an attractive company due to its promising pipeline, and extensive portfolio. The company’s technology has shown differentiated safety profiles and efficacy data in various cancers. With a consensus Buy rating from industry analysts, the stock has a target price of $39.27, which represents a 38.97% upside potential from its current level.
